Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Viatris is a global generic and specialty pharmaceutical company formed from the 2020 merger of Mylan and Pfizer's Upjohn division, operating 40+ manufacturing facilities across North America, Europe, Greater China, and India. The company markets a portfolio of 1,400+ molecules spanning biosimilars, complex generics, and legacy branded products including Lipitor, Lyrica, and Viagra, with significant exposure to government reimbursement systems and patent cliff dynamics. Despite negative reported margins due to merger-related charges and restructuring, the business generates $2.3B in operating cash flow with a 10.9% FCF yield, positioning it as a value/turnaround play in the commoditized generics space.
Viatris operates a high-volume, low-margin model leveraging vertical integration across API manufacturing, formulation, and global distribution networks. Revenue derives from selling off-patent molecules at 70-90% discounts to branded equivalents, competing on manufacturing scale, regulatory expertise (505(b)(2) filings, biosimilar approvals), and pharmacy/GPO contracting relationships. Pricing power is minimal in developed markets due to government price controls (Europe) and PBM/payer pressure (US), but the company maintains 38% gross margins through manufacturing footprint optimization, API backward integration at facilities in India and China, and portfolio mix toward higher-barrier complex generics (inhalers, transdermals, injectables). The 2020 merger created $1B+ in targeted synergies through facility rationalization, procurement leverage, and SG&A reduction.
Generic drug pricing trends in US market - Medicaid rebate changes, PBM formulary decisions, and competitive intensity for key molecules
Biosimilar launch execution and market share capture - particularly Humira biosimilar (Hulio/Yusimry) penetration in US/EU markets
Debt reduction progress and deleveraging trajectory - current 0.97x D/E with $2B FCF enabling accelerated paydown
Complex generics pipeline approvals - 505(b)(2) products, respiratory devices, and high-barrier injectables with limited competition
China market performance - government volume-based procurement (VBP) pricing impact on legacy Upjohn brands
Persistent generic pricing erosion - US market faces structural deflation from increased competition, PBM consolidation, and government price negotiation expansion under IRA legislation
Regulatory and quality compliance - FDA warning letters, facility shutdowns, or import bans (particularly at India/China API sites) can disrupt supply chains and trigger revenue loss
Biosimilar competitive intensity - as Humira, Stelara, and other blockbusters face biosimilar waves, pricing may collapse faster than anticipated, limiting revenue upside from launches
Scale competitors with lower cost structures - Teva, Sandoz, Dr. Reddy's compete aggressively on price for commodity generics, compressing margins
Vertical integration by PBMs and payers - CVS/Caremark, Cigna/Express Scripts developing captive generic sourcing threatens independent manufacturers' market access
Elevated debt load - $8.9B net debt (0.97x D/E) from merger financing requires $2B+ annual FCF for deleveraging, limiting capital allocation flexibility for R&D or M&A
Pension and restructuring liabilities - legacy Upjohn/Mylan defined benefit plans and ongoing facility rationalization create cash outflow variability
low - Pharmaceutical demand is non-discretionary and largely insulated from GDP fluctuations. Generic prescriptions remain stable through recessions as patients prioritize essential medications. However, emerging markets revenue (~30% of total) shows moderate sensitivity to local GDP growth and currency fluctuations, particularly in Latin America and MENA regions where out-of-pocket spending dominates.
Rising rates increase financing costs on $8.9B debt load (0.97x D/E), though much is fixed-rate from merger financing. Higher rates compress valuation multiples for low-growth pharma stocks as investors rotate toward bonds. Conversely, strong FCF generation ($2B annually) enables debt paydown regardless of rate environment, reducing refinancing risk. Rate sensitivity is moderate - impacts valuation more than operations.
Minimal direct credit exposure. Revenue comes from government payers (Medicare/Medicaid), large insurers, and hospital systems with strong credit profiles. Receivables risk is low. However, government budget pressures during recessions can accelerate reimbursement cuts and Medicaid rebate increases, indirectly tightening pricing. Credit conditions affect M&A capacity for bolt-on acquisitions but not core operations.
value - Investors focus on 10.9% FCF yield, 1.3x P/S valuation, and debt paydown story. The 46% 1-year return reflects re-rating as merger integration progresses and deleveraging accelerates. Attracts deep value funds seeking mispriced turnarounds with hidden asset value in manufacturing network and biosimilar pipeline. Not a growth story - revenue declining 4.5% YoY due to pricing headwinds.
moderate - Pharma stocks exhibit lower beta than market (~0.7-0.9) due to non-cyclical demand, but Viatris faces elevated volatility from merger integration execution risk, debt load concerns, and binary events (biosimilar launches, FDA approvals, debt refinancing). Recent 44.5% 3-month surge indicates high volatility during re-rating periods.
